Search

Your search keyword '"Dermatologic agents -- Product development"' showing total 253 results
Start Over Descriptor "Dermatologic agents -- Product development" Topic clinical trials
253 results on '"Dermatologic agents -- Product development"'

1. Alumis announces OLE data from phase 2 STRIDE clinical trial of ESK-001 to treat psoriasis

Subjects
Psoriasis, Dermatology -- Formulae, receipts, prescriptions, Clinical trials, Dermatologic agents -- Product development, Pharmaceuticals and cosmetics industries
Abstract

Alumis Inc, a clinical stage biopharmaceutical company developing oral therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of patients with immune-mediated diseases, announced positive [...]

Published
2024

2. Late-Breaking Data at EADV of ESK-001, an Oral TYK2 Inhibitor for the Treatment of Psoriasis, Demonstrate Significant Responses with Sustained Increases Over 28 Weeks in Phase 2 OLE Study

Subjects
Psoriasis -- Drug therapy, Dermatology -- Formulae, receipts, prescriptions, Clinical trials, Dermatologic agents -- Product development, General interest, News, opinion and commentary
Abstract

SOUTH SAN FRANCISCO: Alumis Inc. a clinical stage biopharmaceutical company developing oral therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of patients with immune-mediated [...]

Published
2024

3. Research on Eczema Published by a Researcher at University of Bristol (Capturing and reporting topical treatment use in childhood eczema: lessons for data collection in eczema trials)

Subjects
Eczema -- Drug therapy, Dermatology -- Formulae, receipts, prescriptions, Data entry, Clinical trials, Dermatologic agents -- Product development, Health, University of Bristol
Abstract

2024 SEP 6 (NewsRx) -- By a News Reporter-Staff News Editor at Health & Medicine Week -- Investigators discuss new findings in eczema. According to news reporting out of Bristol, [...]

Published
2024

4. Huaotai HB0017 (IL-17A monoclonal antibody) injection for treatment of plaque psoriasis successfully completed the enrollment of patients in the key Phase III clinical trial

Subjects
Psoriasis -- Drug therapy, Dermatology -- Formulae, receipts, prescriptions, Clinical trials, Dermatologic agents -- Product development, Interleukins -- Product development, Monoclonal antibodies, Business, Business, international
Abstract

Key Highlight: * Shanghai Huaotai Biopharmaceutical Co., Ltd. announced that the key Phase III clinical trial of its independently developed HB0017 injection successfully completed the enrollment of all subjects on [...]

Published
2024

5. SFA Therapeutics Announces Completion of Enrollment in Phase 1b Trial of SFA-002 for Psoriasis

Subjects
Psoriasis -- Care and treatment, Dermatology -- Formulae, receipts, prescriptions, Clinical trials, Dermatologic agents -- Product development, Business, News, opinion and commentary
Abstract

JENKINTOWN, Pa., May 30, 2024 /PRNewswire/ -- SFA Therapeutics, Inc., a clinical-stage biopharmaceutical company developing oral small molecule biosynthetic compounds for the treatment of inflammatory diseases, today announced the completion [...]

Published
2024

6. InnoCare Announces the Completion of Patient Enrollment in the Phase II Clinical Trial of ICP-488 for the Treatment of Psoriasis

Subjects
Psoriasis -- Drug therapy, Medical research, Medicine, Experimental, Dermatology -- Formulae, receipts, prescriptions, Clinical trials, Dermatologic agents -- Product development, Business, Business, international
Abstract

BEIJING -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, today announced the completion of patient enrollment for the [...]

Published
2024

7. InnoCare Announces the Completion of Patient Enrollment in the Phase II Clinical Trial of ICP-488 for the Treatment of Psoriasis

Subjects
Psoriasis -- Drug therapy, Medical research, Medicine, Experimental, Dermatology -- Formulae, receipts, prescriptions, Clinical trials, Dermatologic agents -- Product development, General interest, News, opinion and commentary
Abstract

BEIJING: INNOCARE PHARMA has issued the following news release: InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, today announced [...]

Published
2024

8. Eczema Pipeline Outlook, FDA Approvals, Clinical Trials and Companies 2024 (Updated)

Subjects
Business -- Research, Clobetasone -- Product development, Eczema, Dermatology -- Formulae, receipts, prescriptions, Drug approval, Clinical trials, Dermatologic agents -- Product development, Alitretinoin -- Product development, Business, Business, international
Abstract

M2 PRESSWIRE-May 9, 2024-: Eczema Pipeline Outlook, FDA Approvals, Clinical Trials and Companies 2024 (Updated) (C)1994-2024 M2 COMMUNICATIONS RDATE:08052024 DelveInsight, 'Eczema Pipeline Insight 2024' report provides comprehensive insights about 100+ [...]

Published
2024

9. InnoCare Pharma begins patient dosing in clinical trial of TYK2 JH2 allosteric inhibitor ICP-488 in China

Subjects
Psoriasis -- Drug therapy, Medical research, Medicine, Experimental, Dermatology -- Formulae, receipts, prescriptions, Clinical trials, Dermatologic agents -- Product development, Pharmaceuticals and cosmetics industries
Abstract

InnoCare Pharma, a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced the first psoriasis patient has been dosed in clinical trial of the company's TYK2 [...]

Published
2023

10. Journey Medical Corporation Announces Presentation of Data from Phase 1 Clinical Trial Assessing the Impact of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) on Microbial Flora of Healthy Adults at 2024 AAD Annual Meeting

Subjects
Medical research, Medicine, Experimental, Skin diseases -- Drug therapy, Dermatology -- Formulae, receipts, prescriptions, Drug approval, Clinical trials, Dermatologic agents -- Product development, Banking, finance and accounting industries, Business
Abstract

Clinical trial achieved all three primary objectives and subjects completed 16-week treatment with no significant safety issues Results indicate that DFD-29 can be safely used for up to 16 weeks [...]

Published
2024

11. Dermavant to Present New ADORING Data Including Treatment of Patients with Skin of Color from Phase 3 Trials of VTAMA[R] (tapinarof) Cream, 1% in Adults and Children 2 Years of Age and Older with Atopic Dermatitis at the 2024 AAD Annual Meeting

Subjects
Atopic dermatitis, Dermatology -- Formulae, receipts, prescriptions, Clinical trials, Skin, Dermatologic agents -- Product development, Business, Business, international, Vtama (Medication) -- Product development
Abstract

- Four poster presentations, including two oral presentations, will highlight the clinical data for VTAMA cream for the treatment of atopic dermatitis in adults and children 2 years of age [...]

Published
2024

12. Eirion Therapeutics Announces Initiation of First-in-Human Clinical Trial Evaluating Next Generation, Ready-to-Use Liquid Injectable Neuromodulator AI-09 for the Treatment of Wrinkles

Subjects
Medical research, Medicine, Experimental, Dermatology -- Formulae, receipts, prescriptions, Clinical trials, Dermatologic agents -- Product development, Physical fitness, Health
Abstract

2022 NOV 5 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Eirion Therapeutics Inc. announced that the first participants have been dosed in [...]

Published
2022

13. Effectiveness and safety of ozone therapy for dermatological disorders: A literature review of clinical trials

Author

Machado, Andressa and Contri, Renata

Subjects
Medical research, Medicine, Experimental, Antioxidants -- Product development, Dermatology -- Formulae, receipts, prescriptions, Clinical trials, Dermatologic agents -- Product development, Air pollution, Health
Abstract

Byline: Andressa. Machado, Renata. Contri Ozone is a strong oxidizing agent, capable of promoting therapeutic effects such as antimicrobial, anti inflammatory, antioxidant and healing activities, with low probability of toxicity [...]

Published
2022

14. Psoriasis Pipeline, FDA Approvals, Clinical Trials Development, and Companies 2023 | Mylan, Biocad, Bristol-Myers Squibb, Celltrion, Coherus BioSciences, Janssen Pharmaceuticals, Can-Fite Biopharma

Subjects
Mylan Pharmaceuticals Inc. -- Product development, Bristol-Myers Squibb Co. -- Product development, Psoriasis, Biological products industry -- Product development, Business -- Research, Dermatology -- Formulae, receipts, prescriptions, Adalimumab -- Product development, Clinical trials, Dermatologic agents -- Product development, Pharmaceutical industry -- Product development, Roflumilast -- Product development, Business, Business, international, Humira (Medication) -- Product development
Abstract

M2 PRESSWIRE-December 5, 2023-: Psoriasis Pipeline, FDA Approvals, Clinical Trials Development, and Companies 2023 | Mylan, Biocad, Bristol-Myers Squibb, Celltrion, Coherus BioSciences, Janssen Pharmaceuticals, Can-Fite Biopharma (C)1994-2023 M2 COMMUNICATIONS RDATE:04122023 [...]

Published
2023

15. Phio Pharmaceuticals Announces First US Patient Enrolled in Phase 1B Clinical Trial with Intratumoral PH-762 anti-PD-1 Therapy for Treatment of Skin Carcinomas

Subjects
Dermatology -- Formulae, receipts, prescriptions, Skin -- Care and treatment, Cancer -- Care and treatment, Clinical trials, Dermatologic agents -- Product development, General interest, News, opinion and commentary
Abstract

MARLBOROUGH: Phio Pharmaceuticals Corp. has issued the following press release: Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYLtm RNAi platform technology is designed to make [...]

Published
2023

16. Phio Pharmaceuticals Announces First US Patient Enrolled in Phase 1B Clinical Trial with Intratumoral PH-762 anti-PD-1 Therapy for Treatment of Skin Carcinomas

Subjects
T cells, Dermatology -- Formulae, receipts, prescriptions, Skin -- Care and treatment, Cancer -- Care and treatment, Clinical trials, Dermatologic agents -- Product development, Banking, finance and accounting industries, Business
Abstract

MARLBOROUGH, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL(TM) RNAi platform technology is designed to make immune cells [...]

Published
2023

17. Lipidor updates on Phase III study of AKP02 in treatment of psoriasis - half of patients now recruited

Subjects
Psoriasis -- Care and treatment, Dermatology -- Formulae, receipts, prescriptions, Clinical trials, Dermatologic agents -- Product development, Physical fitness, Industry hiring, Health
Abstract

2022 JUN 4 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) announces that half [...]

Published
2022

18. InnoCare Reports First Psoriasis Patient Dosed in Clinical Trial of TYK2 Allosteric Inhibitor ICP-488 in China

Subjects
Psoriasis -- Drug therapy, Medical research, Medicine, Experimental, Dermatology -- Formulae, receipts, prescriptions, Clinical trials, Dermatologic agents -- Product development, General interest, News, opinion and commentary
Abstract

BEIJING: InnoCare Pharma , a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced the first psoriasis patient has been dosed in clinical trial of the [...]

Published
2023

19. Journey Medical Corporation Announces Positive Topline Data from Phase 1 Clinical Trial Assessing the Impact of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) on Microbial Flora of Healthy Adult Subjects

Subjects
Dr. Reddy's Laboratories Ltd. -- Product development, Medical research, Medicine, Experimental, Skin diseases -- Drug therapy, Dermatology -- Formulae, receipts, prescriptions, Minocycline -- Product development, Clinical trials, Drug approval, Dermatologic agents -- Product development, Adults, Pharmaceutical industry -- Product development, General interest, News, opinion and commentary, Oracea (Medication) -- Product development
Abstract

SCOTTSDALE: Journey Medical Corporation has issued the following press release: Journey Medical Corporation (Nasdaq: DERM) ('Journey Medical'), a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of [...]

Published
2023

20. Phio Pharmaceuticals Announces FDA Clearance to Initiate Clinical Trial of PH-762 for Treatment of Skin Carcinomas

Subjects
United States. Food and Drug Administration -- Planning, T cells, Dermatology -- Formulae, receipts, prescriptions, Cancer -- Care and treatment, Clinical trials, Skin, Dermatologic agents -- Product development, Company business planning, Business, News, opinion and commentary
Abstract

MARLBOROUGH, Mass., May 16, 2023 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL[sup.(TM)] RNAi platform technology is designed to make immune cells more [...]

Published
2023

21. Sareum receives Australian approval for psoriasis drug clinical trial

Subjects
Psoriasis -- Drug therapy, Dermatology -- Formulae, receipts, prescriptions, Clinical trials, Drug approval, Dermatologic agents -- Product development, Business, international
Abstract

London: Sareum Holdings PLC has issued the following press release: Sareum Holdings PLC on Friday said its application to start a phase 1 clinical trial in Australia of its lead [...]

Published
2023

22. Journey Medical Corporation Announces Completion of Treatment Assessing Impact of DFD-29 (Minocycline Modified Release Capsules 40 mg) on Microbial Flora in a Separate Phase 1 Clinical Trial

Subjects
Dr. Reddy's Laboratories Ltd. -- Product development, Medical research, Medicine, Experimental, Skin diseases, Dermatology -- Formulae, receipts, prescriptions, Minocycline -- Product development, Clinical trials, Dermatologic agents -- Product development, Pharmaceutical industry -- Product development, General interest, News, opinion and commentary
Abstract

SCOTTSDALE, Ariz: Journey Medical Corporation has issued the following news release: Journey Medical Corporation (Nasdaq: DERM) ('Journey Medical'), a commercial-stage biopharmaceutical company that focuses on the development and commercialization of [...]

Published
2023

23. Journey Medical Corporation Announces Completion of Treatment Assessing Impact of DFD-29 (Minocycline Modified Release Capsules 40 mg) on Microbial Flora in a Separate Phase 1 Clinical Trial

Subjects
Medical research, Medicine, Experimental, Skin diseases, Dermatology -- Formulae, receipts, prescriptions, Minocycline -- Product development, Clinical trials, Dermatologic agents -- Product development, Banking, finance and accounting industries, Business
Abstract

Subjects completed 16-week treatment with no significant safety issues Topline results expected in the first half of 2023 SCOTTSDALE, Ariz., March 16, 2023 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: [...]

Published
2023

24. New drug treatment for eczema is 'highly effective' trials show; It has already been approved in the US and should now be made available in the UK

Subjects
Medical research, Medicine, Experimental, Eczema -- Drug therapy, Dermatology -- Formulae, receipts, prescriptions, Clinical trials, Dermatologic agents -- Product development, General interest, News, opinion and commentary
Abstract

Byline: By, Neil Shaw A new drug therapy to treat moderate to severe eczema in young children has been shown to be 'safe and highly effective' in clinical trials. In [...]

Published
2022

25. RenovaCare to start clinical trial at U.S. burn centers

Subjects
Stem cells -- Transplantation, Dermatology -- Formulae, receipts, prescriptions, Clinical trials, Dermatologic agents -- Product development, Business, News, opinion and commentary
Abstract

RenovaCare announced that it is initiating a clinical trial at four burn centers in the United States. This follows the Company's recent Investigational Device Exemption approval by the U.S. Food [...]

Published
2021

26. Vial Announced Enrollment of First Patient in Phase II Clinical Trial TLL018-205 for the Treatment of Plaque Psoriasis Sponsored by Highlightll Pharmaceutical

Subjects
Psoriasis, Dermatology -- Formulae, receipts, prescriptions, Clinical trials, Dermatologic agents -- Product development, General interest, News, opinion and commentary
Abstract

SAN FRANCISCO: Vial, a global tech-enabled CRO providing next-generation clinical trial management services, announced that the first patient has been enrolled in the clinical trial TLL018-205, a Phase II, randomized, [...]

Published
2023

27. Vial Announces Enrollment of First Patient in Phase II Clinical Trial TLL018-205 for the Treatment of Plaque Psoriasis Sponsored by Highlightll Pharmaceutical

Subjects
Psoriasis, Medical research, Medicine, Experimental, Dermatology -- Formulae, receipts, prescriptions, Clinical trials, Dermatologic agents -- Product development, Business, News, opinion and commentary
Abstract

SAN FRANCISCO, Jan. 19, 2023 /PRNewswire/ -- https://c212.net/c/link/?t=0&l=en&o=3761652-1&h=3201705382&u=http%3A%2F%2Fwww.vial.com%2F%3Futm_source%3Dprnewswire%26utm_medium%3Darticle%26utm_campaign%3Dhll_fpi&a=Vial, a global tech-enabled CRO providing next-generation clinical trial management services, announced that the first patient has been enrolled in the clinical trial [...]

Published
2023

28. DermBiont Reports Positive Data from Its Phase 2 Trial with 0.8% SM-030 Gel

Subjects
Skin diseases -- Care and treatment, Dermatology -- Formulae, receipts, prescriptions, Clinical trials, Skin, Dermatologic agents -- Product development, Business, Business, international, Telecommunications industry
Abstract

DermBiont, a clinical-stage biotechnology company that is advancing targeted topical therapeutics for the treatment of dermatological indications, reported positive data from its Phase 2 trial with 0.8 percent SM-030 gel, [...]

Published
2023

29. Phio Pharmaceuticals Announces FDA Clearance to Initiate Clinical Trial of PH-762 for Treatment of Skin Carcinomas

Subjects
United States. Food and Drug Administration -- Planning, T cells, Dermatology -- Formulae, receipts, prescriptions, Cancer -- Care and treatment, Clinical trials, Skin, Dermatologic agents -- Product development, Company business planning, Government, Political science
Abstract

2023 JUN 1 (VerticalNews) -- By a News Reporter-Staff News Editor at Politics & Government Week -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL[TM] [...]

Published
2023

30. Lynk Pharmaceuticals doses first cohort of psoriatic subjects in LNK01004 Phase Ib clinical trial

Subjects
Psoriasis, Dermatology -- Formulae, receipts, prescriptions, Clinical trials, Dermatologic agents -- Product development, Chemistry
Abstract

M2 PHARMA-May 26, 2023-Lynk Pharmaceuticals doses first cohort of psoriatic subjects in LNK01004 Phase Ib clinical trial (C)2023 M2 COMMUNICATIONS Lynk Pharmaceuticals Co., Ltd., a China-based innovative clinical stage pharmaceutical [...]

Published
2023

31. Lynk Pharmaceuticals doses first cohort of psoriatic subjects in LNK01004 Phase Ib clinical trial

Subjects
Psoriasis, Dermatology -- Formulae, receipts, prescriptions, Clinical trials, Dermatologic agents -- Product development, Business
Abstract

M2 EQUITYBITES-May 26, 2023-Lynk Pharmaceuticals doses first cohort of psoriatic subjects in LNK01004 Phase Ib clinical trial (C)2023 M2 COMMUNICATIONS http://www.m2.co.uk Lynk Pharmaceuticals Co., Ltd., a China-based innovative clinical stage [...]

Published
2023

32. Arcutis Biotherapeutics to accelerate ARQ-151 into Phase 3 trials

Subjects
United States. Food and Drug Administration -- Planning, Clinical trials, Atopic dermatitis, Dermatologic agents -- Product development, Psoriasis, Roflumilast -- Product development, Company business planning, Business, News, opinion and commentary
Abstract

Arcutis Biotherapeutics y announced plans to advance its program to develop ARQ-151 for the treatment of atopic dermatitis into Phase 3 clinical trials following its End-of-Phase 2 meeting with the [...]

Published
2020

33. Eirion Therapeutics Announces Initiation of First-in-Human Clinical Trial Evaluating Next Generation, Ready-to-Use Liquid Injectable Neuromodulator AI-09 for the Treatment of Wrinkles

Subjects
Dermatology -- Formulae, receipts, prescriptions, Clinical trials, Dermatologic agents -- Product development, General interest, News, opinion and commentary
Abstract

WOBURN: Eirion has issued the following news release: Eirion Therapeutics Inc. announced today that the first participants have been dosed in a Phase 1/2 clinical trial for the treatment of [...]

Published
2022

34. Eirion Therapeutics Announces Initiation of First-in-Human Clinical Trial Evaluating Next Generation, Ready-to-Use Liquid Injectable Neuromodulator AI-09 for the Treatment of Wrinkles

Subjects
Dermatology -- Formulae, receipts, prescriptions, Clinical trials, Dermatologic agents -- Product development, Business, News, opinion and commentary
Abstract

Company Also Announces Update for Its Lead, Phase 2b Product CandidateTopical Neuromodulator ET-01 WOBURN, Mass., Oct. 17, 2022 /PRNewswire/ -- Eirion Therapeutics Inc. announced today that the first participants have [...]

Published
2022

35. Alumis Announces Initiation of Patient Dosing in Phase 2 Clinical Trial of ESK-001 for the Treatment of Plaque Psoriasis

Subjects
Psoriasis -- Drug therapy, Dermatology -- Formulae, receipts, prescriptions, Clinical trials, Dermatologic agents -- Product development, General interest, News, opinion and commentary
Abstract

SOUTH SAN FRANCISCO, Calif.: Alumis Inc. has issued the following news release: Alumis Inc., a precision immunology company that is reimagining the discovery, development and treatment of autoimmune disorders, today [...]

Published
2022

36. Azura Ophthalmics Provides Update on AZR-MD-001 Phase 2 Clinical Program Targeting Meibomian Gland Dysfunction

Subjects
United States. Food and Drug Administration, Eye diseases, Dermatology -- Formulae, receipts, prescriptions, Clinical trials, Dermatologic agents -- Product development, General interest, News, opinion and commentary
Abstract

TEL AVIV, Israel & MELBOURNE, Australia: Azura Ophthalmics Ltd. has issued the following news release: Azura Ophthalmics Ltd., a clinical-stage biopharmaceutical company developing a new therapeutic class of Ophthalmic Keratolytics [...]

Published
2022

37. Alumis Announces Initiation of Patient Dosing in Phase 2 Clinical Trial of ESK-001 for the Treatment of Plaque Psoriasis

Subjects
Psoriasis -- Drug therapy, Dermatology -- Formulae, receipts, prescriptions, Clinical trials, Dermatologic agents -- Product development, Business, Business, international
Abstract

Phase 2 Initiation Supported by Positive Data from Phase 1 Studies in which ESK-001 was Generally Well-Tolerated and Demonstrated Full, Sustained TYK2 Inhibition SOUTH SAN FRANCISCO, Calif. -- Alumis Inc., [...]

Published
2022

38. Azura Ophthalmics Provides Update on AZR-MD-001 Phase 2 Clinical Program Targeting Meibomian Gland Dysfunction

Subjects
United States. Food and Drug Administration, Eye diseases, Dermatology -- Formulae, receipts, prescriptions, Clinical trials, Dermatologic agents -- Product development, Selenium sulfide -- Product development, Business, Business, international
Abstract

Receives IND clearance for Phase 2b program in U.S. Topline data from ongoing Phase 2b clinical trial to be reported in Q4 2022 TEL AVIV, Israel & MELBOURNE, Australia -- [...]

Published
2022

39. MC2 Therapeutics announces initiation of a Phase 2 clinical trial in CKD-aP

Subjects
Skin diseases, Dermatology -- Formulae, receipts, prescriptions, Clinical trials, Dermatologic agents -- Product development, Kidney diseases, General interest, News, opinion and commentary
Abstract

COPENHAGEN: MC2 Therapeutics has issued the following news release: MC2 Therapeutics A/S, a commercial stage pharmaceutical company, engaged in research in skin biology and development of novel treatment paradigms for [...]

Published
2022

40. Study Findings on Bacterial Infections and Mycoses Discussed by Researchers at University of Yaounde 1 (A randomized controlled trial evaluating the efficacy and safety of a MYCOFUNGI CREAM in patients with skin mycoses)

Subjects
Medical research, Medicine, Experimental, Dermatology -- Formulae, receipts, prescriptions, Bacterial infections -- Drug therapy, Infection -- Drug therapy, Antifungal agents -- Product development, Clinical trials, Skin, Dermatologic agents -- Product development, Skin care products -- Product development, Health
Abstract

2023 MAR 31 (NewsRx) -- By a News Reporter-Staff News Editor at Health & Medicine Week -- Data detailed on bacterial infections and mycoses have been presented. According to news [...]

Published
2023

41. DICE Therapeutics Announced Completion of Enrollment in Phase 1 Clinical Trial of Lead Oral IL-17 Antagonist, DC-806, for the Treatment of Psoriasis

Subjects
Psoriasis -- Drug therapy, Chronic diseases -- Drug therapy, Dermatology -- Formulae, receipts, prescriptions, Clinical trials, Dermatologic agents -- Product development, Interleukins -- Product development, Business, international
Abstract

SOUTH SAN FRANCISCO: DICE Therapeutics, Inc. (Nasdaq: DICE), a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in [...]

Published
2022

42. Lipidor updates on Phase III study of AKP02 in treatment of psoriasis - half of patients now recruited

Subjects
Psoriasis -- Care and treatment, Dermatology -- Formulae, receipts, prescriptions, Clinical trials, Dermatologic agents -- Product development, Industry hiring, General interest, News, opinion and commentary
Abstract

STOCKHOLM: Lipidor has issued the following news release: Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) announces that half of the patients have now been enrolled in the Phase [...]

Published
2022

43. Lipidor updates on Phase III study of AKP02 in treatment of psoriasis - half of patients now recruited

Subjects
Psoriasis -- Care and treatment, Dermatology -- Formulae, receipts, prescriptions, Clinical trials, Dermatologic agents -- Product development, Industry hiring, Business, News, opinion and commentary
Abstract

STOCKHOLM, May 20, 2022 /PRNewswire/ -- Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) announces that half of the patients have now been enrolled in the Phase III study [...]

Published
2022

44. Durect plunges after scrapping psoriasis drug development following trial

Subjects
Dermatologic agents -- Product development, Psoriasis -- Drug therapy, Clinical trials, Business, News, opinion and commentary
Abstract

Shares of Durect (DRRX) are under pressure on Thursday after the company announced the results from its Phase 2a clinical trial of DUR-928 in patients with mild to moderate plaque [...]

Published
2020

45. Piclidenoson Destroys Pathological Skin Cells in Vitro Prior to Phase III Psoriasis Data Release, Can Fite Reports

Subjects
Can-Fite BioPharma Ltd. -- Product development, Psoriasis, Dermatology -- Formulae, receipts, prescriptions, Clinical trials, Skin, Dermatologic agents -- Product development, Pharmaceutical industry -- Product development, General interest, News, opinion and commentary
Abstract

PETACH TIKVA: Can-Fite BioPharma Ltd., a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced that pre-clinical studies with skin [...]

Published
2022

46. Prior to Phase III Psoriasis Data Release Can Fite Reports that Piclidenoson Destroys Pathological Skin Cells in vitro

Subjects
Can-Fite BioPharma Ltd. -- Product development, Psoriasis -- Care and treatment, Medical research, Medicine, Experimental, Dermatology -- Formulae, receipts, prescriptions, Clinical trials, Liver cancer -- Care and treatment, Skin, Dermatologic agents -- Product development, Pharmaceutical industry -- Product development, Business, Business, international
Abstract

Piclidenoson has been out-licensed for the indication of psoriasis in certain major markets PETACH TIKVA, Israel -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI), a biotechnology company advancing a [...]

Published
2022

47. Aslan teams up with IQVIA to test eczema drug in international phase 2b trial

Author

LaHucik, Kyle

Subjects
Atopic dermatitis, Dermatology -- Formulae, receipts, prescriptions, Clinical trials, Dermatologic agents -- Product development, Biotechnology industry, Dupixent (Medication) -- Product development
Abstract

Byline: Kyle LaHucik Aslan Pharmaceuticals is ready to hit go on decentralized clinical trials after the uncertainty of the COVID-19 pandemic forced it into pausing one of its trials for [...]

Published
2021

48. DICE Therapeutics Initiates Phase 1 Clinical Trial of S011806 for the Treatment of Psoriasis

Subjects
Psoriasis -- Drug therapy, Chronic diseases -- Drug therapy, Dermatology -- Formulae, receipts, prescriptions, Clinical trials, Dermatologic agents -- Product development, Interleukins -- Product development, Banking, finance and accounting industries, Business
Abstract

SOUTH SAN FRANCISCO, Calif., Oct 25, 2021 (GLOBE NEWSWIRE via COMTEX) -- DICE Therapeutics, Inc. (Nasdaq: DICE), a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of [...]

Published
2021

49. DICE Therapeutics, Inc. Initiates Phase 1 Clinical Trial of S011806 for the Treatment of Psoriasis

Subjects
Psoriasis -- Drug therapy, Dermatology -- Formulae, receipts, prescriptions, Clinical trials, Dermatologic agents -- Product development, General interest, News, opinion and commentary
Abstract

SOUTH SAN FRANCISCO, Calif.,; DICE Therapeutics, Inc. (Nasdaq: DICE), a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases [...]

Published
2021

50. Lipidor announces approval to start Phase III clinical study of drug candidate AKP02 for treatment of psoriasis

Subjects
Psoriasis -- Drug therapy, Dermatology -- Formulae, receipts, prescriptions, Drug approval, Clinical trials, Dermatologic agents -- Product development, General interest, News, opinion and commentary, Enstilar (Medication) -- Product development
Abstract

STOCKHOLM: Lipidor has issued the following news release: Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) announced today that the company's Phase III clinical study of its drug candidate [...]

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results